专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6086898A Method of converting a Th2-type allergic immune response into a Th1-type immune response 失效
标题翻译：将Th2型过敏免疫反应转化为Th1型免疫应答的方法
公开(公告)号：US6086898A
公开(公告)日：2000-07-11
申请号：US339068
申请日：1999-06-23
申请人： Rosemarie H. DeKruyff , Dale T. Umetsu
发明人： Rosemarie H. DeKruyff , Dale T. Umetsu
IPC分类号： A61K45/00 , A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , A61K39/39 , A61K39/395 , A61P11/06 , A61P29/00 , A61P37/02 , A61P37/08 , A61P43/00
CPC分类号： A61K39/39 , A61K39/35 , A61K2039/55594 , A61K2039/57
摘要： Methods are provided for the treatment of allergic and other immune disorders associated with overproduction of Th2 type cytokines by antigen specific T cells. Immunotherapy with adjuvants, as provided in the present invention, greatly inhibits the development of airway hyperreactivity and airway inflammation. Such immunotherapy is shown to reverse ongoing airway disease, and convert allergic inflammatory responses into protective immune responses. Conditions of particular interest include allergic conditions associated with production of Th2 cytokines and/or IgE antibodies, asthma, allergic rhinitis, and anaphylactic reactions. The addition of adjuvant induces a Th1-type immune response and can redirect an established Th2-type response to a Th1-type response for the selected antigen. Preferably, antigen-specific IgE production is reduced without altering the intensity of the antigen-specific proliferative response. One particularly preferred adjuvant for use in accordance with the present invention is a Listeria adjuvant.
摘要翻译：提供了用于治疗与由抗原特异性T细胞过度产生Th2型细胞因子相关的过敏性和其它免疫疾病的方法。如本发明提供的用佐剂进行免疫治疗极大地抑制气道高反应性和气道炎症的发展。这种免疫治疗显示可逆转正在进行的气道疾病，并将过敏性炎症反应转化为保护性免疫应答。特别感兴趣的条件包括与产生Th2细胞因子和/或IgE抗体相关的过敏症状，哮喘，过敏性鼻炎和过敏反应。佐剂的添加诱导Th1型免疫应答，并可将已建立的Th2型应答重定向至所选抗原的Th1型应答。优选地，减少抗原特异性IgE产生而不改变抗原特异性增殖反应的强度。根据本发明使用的一种特别优选的佐剂是利斯特氏菌佐剂。

3. 发明授权

US07214380B1 Adjuvant therapy 失效
标题翻译：辅助疗法
公开(公告)号：US07214380B1
公开(公告)日：2007-05-08
申请号：US09561089
申请日：2000-04-28
申请人： Rosemarie H. DeKruyff , Dale T. Umetsu
发明人： Rosemarie H. DeKruyff , Dale T. Umetsu
IPC分类号： A61K39/35 , A61K39/02
CPC分类号： A61K39/39 , A61K39/35 , A61K2039/55594 , A61K2039/57
摘要： Methods are provided for the treatment of allergic and other immune disorders associated with overproduction of Th2 type cytokines by antigen specific T cells. Immunotherapy with adjuvants, as provided in the present invention, greatly inhibits the development of airway hyperreactivity and airway inflammation. Such immunotherapy is shown to reverse ongoing airway disease, and convert allergic inflammatory responses into protective immune responses. Conditions of particular interest include allergic conditions associated with production of Th2 cytokines and/or IgE antibodies, asthma, allergic rhinitis, and anaphylactic reactions. The addition of adjuvant induces a Th1-type immune response and can redirect an established Th2-type response to a Th1-type response for the selected antigen. Preferably, antigen-specific IgE production is reduced without altering the intensity of the antigen-specific proliferative response. One particularly preferred adjuvant for use in accordance with the present invention is a Listeria adjuvant.
摘要翻译：提供了用于治疗与由抗原特异性T细胞过度产生Th2型细胞因子相关的过敏性和其它免疫疾病的方法。如本发明提供的用佐剂进行免疫治疗极大地抑制气道高反应性和气道炎症的发展。这种免疫治疗显示可逆转正在进行的气道疾病，并将过敏性炎症反应转化为保护性免疫应答。特别感兴趣的条件包括与产生Th2细胞因子和/或IgE抗体相关的过敏症状，哮喘，过敏性鼻炎和过敏反应。佐剂的添加诱导Th1型免疫应答，并可将已建立的Th2型应答重定向至所选抗原的Th1型应答。优选地，减少抗原特异性IgE产生而不改变抗原特异性增殖反应的强度。根据本发明使用的一种特别优选的佐剂是利斯特氏菌佐剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式